References

Diagnostic criteria for common variable immunodeficiency disorders

10.1016/j.jaip.2016.02.023 · 2016 · External reference

State-of-the-art diagnostic evaluation of common variable immunodeficiency

10.1016/j.anai.2021.03.005 · 2021 · External reference

The European Society for immunodeficiencies (ESID) registry working definitions for the clinical diagnosis of inborn errors of immunity

10.1016/j.jaip.2019.02.004 · 2019 · External reference

International Consensus document (ICON): common variable immunodeficiency disorders

10.1016/j.jaip.2015.07.025 · 2016 · External reference

Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions

10.1111/j.1365-2141.2009.07669.x · 2009 · External reference

Primary immunodeficiency diseases in Australia and New Zealand

10.1007/s10875-007-9105-z · 2007 · External reference

Global distribution of common variable immunodeficiency (CVID) in the light of the UNDP human development index (HDI): a preliminary perspective of a rare disease

10.1155/2020/8416124 · 2020 · External reference

Morbidity and mortality in common variable immune deficiency over 4 decades

10.1182/blood-2011-09-377945 · 2012 · External reference

Identification and characterization of a nationwide danish adult common variable immunodeficiency cohort

10.1111/sji.12551 · 2017 · External reference

Gastrointestinal manifestations of common variable immunodeficiency: a mentored review

10.1007/s10620-025-09106-8 · 2025 · External reference

A systematic literature review of CVID reveals pervasive detrimental noninfectious manifestations

10.70962/jhi.20250157 · 2026 · External reference

Malignancy in common variable immunodeficiency: a systematic review and meta-analysis

10.1080/1744666x.2019.1658523 · 2019 · External reference

Common variable immunodeficiency disorders: division into distinct clinical phenotypes

10.1182/blood-2007-11-124545 · 2008 · External reference

Common variable immunodeficiency and autoimmune diseases: a 10-year single-center experience

10.46497/archrheumatol.2024.10729 · 2024 · External reference

A cross-sectional study of health-related quality of life in patients with predominantly antibody deficiency

10.1007/s10875-024-01781-y · 2024 · External reference

Health-related quality of life in primary immunodeficiencies: impact of delayed diagnosis and treatment burden

10.1016/j.clim.2022.108931 · 2022 · External reference

Unresolved reference

External reference

Economic burden of common variable immunodeficiency: annual cost of disease

10.1586/1744666x.2015.1029457 · 2015 · External reference

Common variable immunodeficiency: more pathways than roads to rome

10.1146/annurev-pathmechdis-031521-024229 · 2023 · External reference

Monitoring patients with uncomplicated common variable immunodeficiency: a systematic review

10.1186/s13223-022-00661-7 · 2022 · External reference

Uncovering risk factors of premature mortality in common variable immunodeficiency

10.1016/j.jaip.2025.03.009 · 2025 · External reference

Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study

10.1007/s10875-011-9511-0 · 2011 · External reference

Unresolved reference

External reference

10.3389/fimmu.2017.01740

10.3389/fimmu.2017.01740 · External reference

Memory B cells in common variable immunodeficiency: clinical associations and sex differences

10.1016/j.clim.2008.02.013 · 2008 · External reference

T cell phenotypes in patients with common variable immunodeficiency disorders: associations with clinical phenotypes in comparison with other groups with recurrent infections

10.1111/j.1365-2249.2012.04643.x · 2012 · External reference

B-Cell and T-Cell phenotypes in CVID patients correlate with the clinical phenotype of the disease

10.1007/s10875-010-9424-3 · 2010 · External reference

Late-onset combined immune deficiency: a subset of common variable immunodeficiency with severe T cell defect

10.1086/606059 · 2009 · External reference

Circulating CD21low B cells in common variable immunodeficiency resemble tissue homing, innate-like B cells

10.1073/pnas.0901984106 · 2009 · External reference

Loss of B cell tolerance at the T2/T3a B cell transition is a convergent pathogenic mechanism in common variable immunodeficiency

2025 · External reference

Unresolved reference

External reference

Clinical utility of measuring CD4+ T follicular cells in patients with immune dysregulation

10.1016/j.jaut.2023.103088 · 2023 · External reference

A decreased frequency of regulatory T cells in patients with common variable immunodeficiency

10.1371/journal.pone.0006269 · 2009 · External reference

Regulatory T cell dysfunction in subjects with common variable immunodeficiency complicated by autoimmune disease

10.1016/j.clim.2008.12.006 · 2009 · External reference

Functions of tfh cells in common variable immunodeficiency

10.3389/fimmu.2020.00006 · 2020 · External reference

Utility of serum cytokine testing to differentiate complicated common variable immunodeficiency in resource limited settings

2025 · External reference

BAFF-driven B cell hyperplasia underlies lung disease in common variable immunodeficiency

10.1172/jci.insight.122728 · 2019 · External reference

Portal hypertension in common variable immunodeficiency disorders - a single center analysis on clinical and immunological parameter in 196 patients

10.3389/fimmu.2023.1268207 · 2023 · External reference

Targeted proteomics reveals inflammatory pathways that classify immune dysregulation in common variable immunodeficiency

10.1007/s10875-020-00908-1 · 2021 · External reference

Soluble interleukin-2 receptor is a promising serum biomarker for granulomatous disease in common variable immune deficiency

10.1007/s10875-020-00947-8 · 2021 · External reference

Undetectable IgE association with noninfectious complications of common variable immune deficiency

2025 · External reference

Practice parameter for the diagnosis and management of primary immunodeficiency

10.1016/j.jaci.2015.04.049 · 2015 · External reference

Interlaboratory variability in multiplexed pneumococcal antibody testing

10.1016/j.jaci.2018.10.057 · 2019 · External reference

Questioning the accuracy of currently available pneumococcal antibody testing

10.1016/j.jaci.2018.06.013 · 2018 · External reference

Application of the diagnostic criteria for common variable immunodeficiency in resource-limited settings

10.15586/aei.v50i4.496 · 2022 · External reference

Update: vaccines in primary immunodeficiency

10.1016/j.jaci.2017.12.980 · 2018 · External reference

2025 inborn errors of immunity practice parameter

10.1016/j.anai.2025.10.026 · 2026 · External reference

Functional testing of humoral immunity in the prevnar 20 era

10.1016/j.anai.2024.12.011 · 2025 · External reference

Seeking relevant biomarkers in common variable immunodeficiency

10.3389/fimmu.2022.857050 · 2022 · External reference

10.3389/fimmu.2023.1257398

10.3389/fimmu.2023.1257398 · External reference

Current genetic landscape in common variable immune deficiency

10.1182/blood.2019000929 · 2020 · External reference

Establishing the molecular diagnoses in a cohort of 291 patients with predominantly antibody deficiency by targeted next-generation sequencing: experience from a monocentric study

10.3389/fimmu.2021.786516 · 2021 · External reference

Genetics and clinical phenotypes in common variable immunodeficiency

2023 · External reference

Disparities in genetic testing for inborn errors of immunity

10.1016/j.jaip.2024.11.011 · 2025 · External reference

Therapeutic modalities and clinical outcomes in a large cohort with LRBA deficiency and CTLA4 insufficiency

10.1016/j.jaci.2023.08.004 · 2023 · External reference

A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome

10.1182/blood.2022018546 · 2023 · External reference

Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: a cohort study

10.1016/j.jaci.2016.03.022 · 2016 · External reference

Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: a large patient cohort study

10.1016/j.jaci.2016.06.021 · 2017 · External reference

Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies: a meta-analysis

10.1002/mus.25409 · 2017 · External reference

Differentiating characteristics and evaluating intravenous and subcutaneous immunoglobulin

2019 · External reference

Improving current immunoglobulin therapy for patients with primary immunodeficiency: quality of life and views on treatment

10.2147/ppa.s60771 · 2014 · External reference

Vivaglobin study group. Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency

10.1186/2047-783x-15-6-238 · 2010 · External reference

Immunoglobulin replacement therapy in patients with primary and secondary immunodeficiencies: impact of infusion method on immunoglobulin-specific perceptions of quality of life and treatment satisfaction

10.1186/s13223-024-00939-y · 2025 · External reference

Intravenous and subcutaneous immunoglobulin G replacement therapy

10.2500/aap.2016.37.3987 · 2016 · External reference

Acute renal failure, translocational hyponatremia and hyperkalemia following intravenous immunoglobulin therapy

10.1159/000104424 · 2007 · External reference

Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: a work group report of the AAAAI primary immunodeficiency and altered immune response committees

10.1016/j.jaci.2022.01.025 · 2022 · External reference

Impact of IVIG vs. SCIG on IgG trough level and infection incidence in primary immunodeficiency diseases: a systematic review and meta-analysis of clinical studies

10.1016/j.waojou.2019.100068 · 2019 · External reference

Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies

10.1016/j.clim.2010.06.012 · 2010 · External reference

Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy

10.1111/j.1365-2249.2012.04594.x · 2012 · External reference

Higher doses of subcutaneous IgG reduce resource utilization in patients with primary immunodeficiency

10.1007/s10875-011-9631-6 · 2012 · External reference

Granulomatous lymphocytic Interstitial Lung Disease (GLILD) in common variable immunodeficiency (CVID): a multicenter retrospective study of patients from Italian PID referral centers

10.3389/fimmu.2021.627423 · 2021 · External reference

False positive serum levels of (1-3)-ß-D-Glucan after infusion of intravenous immunoglobulins and time to normalisation

10.1016/j.jinf.2017.10.017 · 2018 · External reference

Transmission of hepatitis B core antibody and galactomannan enzyme immunoassay positivity via immunoglobulin products: a comprehensive analysis

10.1093/cid/ciw222 · 2016 · External reference

Challenge of hepatitis B testing following intravenous immunoglobulin therapy in patients with autoimmune skin diseases

10.1111/1346-8138.16500 · 2022 · External reference

Intravenous immunoglobulin significantly reduces exposure of concomitantly administered anti-C5 monoclonal antibody tesidolumab

10.1111/ajt.15922 · 2020 · External reference

2022 American college of rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases

10.1002/acr.25045 · 2023 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Preventing infections in children and adults with asplenia

10.1182/hematology.2020000117 · 2020 · External reference

Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients

10.1111/j.1365-2141.2011.08880.x · 2011 · External reference

The efficacy and safety of systemic corticosteroids as first line treatment for granulomatous lymphocytic interstitial lung disease

10.1016/j.jaci.2022.12.813 · 2023 · External reference

Rituximab monotherapy is effective as first-line treatment for granulomatous lymphocytic interstitial lung disease (GLILD) in CVID patients

10.1007/s10875-023-01587-4 · 2023 · External reference

Rituximab and antimetabolite treatment of granulomatous and lymphocytic interstitial lung disease in common variable immunodeficiency

10.1016/j.jaci.2020.07.021 · 2021 · External reference

Anti-tumour necrosis factor-alpha therapy for severe enteropathy in patients with common variable immunodeficiency (CVID)

10.1111/j.1365-2249.2007.03481.x · 2007 · External reference

Infliximab therapy for crohn’s-like disease in common variable immunodeficiency complicated by massive intestinal hemorrhage: a case report

10.1186/1756-0500-7-382 · 2014 · External reference

Infliximab for treatment of granulomatous disease in patients with common variable immunodeficiency

10.1007/s10875-014-0079-3 · 2014 · External reference

Autoimmune cytopenias in common variable immunodeficiency are a diagnostic and therapeutic conundrum: an update

10.3389/fimmu.2022.869466 · 2022 · External reference

Treatment of inflammatory complications in common variable immunodeficiency (CVID): current concepts and future perspectives

10.1080/1744666x.2023.2198208 · 2023 · External reference

CVID enteropathy is difficult to treat and shows a heterogeneous histopathology

10.1007/s10875-025-01920-z · 2025 · External reference

Treatment strategies for GLILD in common variable immunodeficiency: a systematic review

10.3389/fimmu.2021.606099 · 2021 · External reference

Mechanism-based strategies for the management of autoimmunity and immune dysregulation in primary immunodeficiencies

10.1016/j.jaip.2016.08.004 · 2016 · External reference

Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4

10.1016/j.jaci.2015.08.036 · 2016 · External reference

Congenital T cell activation impairs transitional to follicular B cell maturation in humans

2024 · External reference

Abatacept restores dysregulated transcriptomic and proteomic profile in disorders of CTLA-4 insufficiency

10.1016/j.jaci.2025.08.027 · 2025 · External reference

Interim analysis: open-label extension study of leniolisib for patients with APDS

10.1016/j.jaci.2023.09.032 · 2024 · External reference

Hepatic manifestations in common variable immunodeficiency associated with mortality and worse Hospital outcomes in nationwide analysis using national readmission database

10.1016/j.jaip.2025.09.021 · 2025 · External reference

Severe deficiency of switched memory B cells (CD27(+)IgM(-)IgD(-)) in subgroups of patients with common variable immunodeficiency: a new approach to classify a heterogeneous disease

10.1182/blood.v99.5.1544 · 2002 · External reference

Common variable immunodeficiency patient classification based on impaired B cell memory differentiation correlates with clinical aspects

10.1023/a:1025373601374 · 2003 · External reference

The EUROclass trial: defining subgroups in common variable immunodeficiency

10.1182/blood-2007-06-091744 · 2008 · External reference

T-bethighCD21low B cells: the need to unify our understanding of a distinct B cell population in health and disease

10.1016/j.coi.2023.102300 · 2023 · External reference

Expansion of a distinct cytotoxic CD4 TFH-cell cluster in lymph nodes of patients with complicated common variable immunodeficiency

10.1016/j.jaci.2025.09.032 · 2026 · External reference

Convergence of cytokine dysregulation and antibody deficiency in common variable immunodeficiency with inflammatory complications

10.1016/j.jaci.2021.06.008 · 2022 · External reference

Role of B cell activating factor in CVID lung disease

10.1016/j.jaci.2015.12.722 · 2016 · External reference

Plasma protein profiling reflects T(H)1-driven immune dysregulation in common variable immunodeficiency

10.1016/j.jaci.2020.01.046 · 2020 · External reference

Systematic benchmark of state-of-the-art variant calling pipelines identifies major factors affecting accuracy of coding sequence variant discovery

10.1186/s12864-022-08365-3 · 2022 · External reference

Genome-wide association identifies diverse causes of common variable immunodeficiency

10.1016/j.jaci.2011.02.039 · 2011 · External reference

Histocompatibility complex status and mendelian randomization analysis in unsolved antibody deficiency

10.3389/fimmu.2020.00014 · 2020 · External reference

Cytomegalovirus drives Vδ1+ γδ T cell expansion and clonality in common variable immunodeficiency

10.1038/s41467-024-48527-3 · 2024 · External reference

Splenomegaly in CVID patients associates with CMV replication and alterations of immune cells and functions

10.1016/j.imlet.2025.107058 · 2025 · External reference

Influence of cytomegalovirus infection on immune cell phenotypes in patients with common variable immunodeficiency

10.1016/j.jaci.2012.02.011 · 2012 · External reference

Autoimmunity and inflammation in CVID: a possible crosstalk between immune activation, gut microbiota, and epigenetic modifications

10.1007/s10875-018-0574-z · 2019 · External reference

The role of chronic norovirus infection in the enteropathy associated with common variable immunodeficiency

10.1038/ajg.2014.432 · 2015 · External reference

CVID enteropathy associated with chronic norovirus infection: background, clinical features, and therapeutic aspects

10.1002/rmv.70081 · 2025 · External reference

Revealing disease subtypes and heterogeneity in common variable immunodeficiency through transcriptomic analysis

10.1038/s41598-024-74728-3 · 2024 · External reference

Unresolved reference

External reference

Role of advanced practice providers in the cardiac intensive care unit team

10.1016/j.jacc.2023.08.061 · 2023 · External reference

Nurse practitioners and physician assistants: an underestimated workforce for older adults with cancer

10.1111/jgs.15931 · 2019 · External reference

Principles supporting dynamic clinical care teams: an American College of Physicians position paper

10.7326/0003-4819-159-9-201311050-00710 · 2013 · External reference

Unresolved reference

External reference

The status of US allergy/immunology physicians in the 21st century: a report from the American Academy of Allergy, Asthma & Immunology Workforce Committee

10.1016/j.jaci.2007.01.040 · 2007 · External reference

Rural health disparities in allergy, asthma, and immunologic diseases: the current state and future direction for clinical care and research

10.1016/j.jaip.2023.11.030 · 2024 · External reference

Access to specialty healthcare in urban versus rural US populations: a systematic literature review

10.1186/s12913-019-4815-5 · 2019 · External reference

Telehealth and allergy services in rural and regional locations that lack specialty services

10.1016/j.jaip.2022.06.025 · 2022 · External reference

Physician awareness and understanding of primary immunodeficiency disorders: a web-based study in Japan

10.1080/25785826.2022.2137966 · 2023 · External reference

Experiences with diagnostic delay among underserved racial and ethnic patients: a systematic review of the qualitative literature

10.1136/bmjqs-2024-017506 · 2025 · External reference

Racial and ethnic disparities in early mortality among patients with inborn errors of immunity

10.1016/j.jaci.2023.09.036 · 2024 · External reference

Clinical disparity of primary antibody deficiency patients at a safety net hospital

10.1016/j.jaip.2021.03.021 · 2021 · External reference

Primary immunodeficiencies in a mesoregion of São Paulo, Brazil: Epidemiologic, clinical, and geospatial approach

10.3389/fimmu.2020.00862 · 2020 · External reference

10.3389/fimmu.2017.00678

10.3389/fimmu.2017.00678 · External reference

Electronic health record signatures identify undiagnosed patients with common variable immunodeficiency disease

10.1126/scitranslmed.ade4510 · 2024 · External reference

A predictive model for identification of pediatric individuals with common variable immunodeficiency through electronic medical records

10.1016/j.jaci.2025.02.032 · 2025 · External reference

Large-scale deep learning analysis to identify adult patients at risk for combined and common variable immunodeficiencies

10.1038/s43856-023-00412-8 · 2023 · External reference